ArticleAmerican journal of respiratory and critical care medicine2018
Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non-Small Cell Lung Cancer.
Article in American journal of respiratory and critical care medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 2 syntheses or guidelines pooled it, 123 citations in OpenAlex.
- The role of COPD in survival of NSCLC patients receiving immune checkpoint inhibitors: A meta-analysis.Biomolecules & biomedicine · 2025Pooled it
- The impact of comorbid COPD on survival outcomes in lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis.Frontiers in immunology · 2025Pooled it
- Contrast-enhanced CT based radiomics for prediction of 3-year disease progression in NSCLC patients after anti-PD-1-targeted therapy.European journal of radiology open · 2026Article
- Prognostic value of diabetes-related clinical indices in patients with non-small cell lung cancer and comorbid type 2 diabetes receiving immune checkpoint inhibitor therapy.Acta diabetologica · 2026Article
- Same tumor, different lungs: How chronic obstructive pulmonary disease and interstitial lung disease reshape lung cancer risk and treatment.Journal of translational internal medicine · 2026Article
- COPD is associated with poorer survival in patients with advanced non-small cell lung cancer treated with first-line ICI plus chemotherapy.BMC pulmonary medicine · 2026Article
- Effects of Astragalus membranaceus injection at Zusanli (ST36) acupoint on lung cancer with COPD.Medical oncology (Northwood, London, England) · 2026Article
- Spatial transcriptomics reveals compartment-specific cytotoxic T cell crosstalk with AT2 and goblet cells in advanced COPD.Biomarker research · 2026Article
- Hallmarks of the ageing lung: 10 years later.The European respiratory journal · 2026Review
- Emphysema Shapes a Pro-Inflammatory Immune Microenvironment in Pulmonary Adenocarcinoma: A Pilot Immune Transcriptomic Profiling Study.International journal of molecular sciences · 2026Article
- Impact of concurrent systemic and inhaled corticosteroid use on clinical outcomes in advanced lung cancer patients receiving immune checkpoint inhibitors.Respiratory research · 2026Article
- Can tissue immune states shape the risk of hyperprogressive disease?Frontiers in immunology · 2026Review
- Single-Cell Transcriptomics Reveals Macrophage Dysfunction and cDC2 Activation in COPD: Candidate Biomarkers for Individualized Nursing Care.International journal of chronic obstructive pulmonary disease · 2026Article
- Evaluating the effect of immune checkpoint inhibitor treatment on chronic obstructive pulmonary disease in lung cancer patients.Oncoimmunology · 2025Article
- Lung tissue T cells are activated in chronic obstructive pulmonary disease with non-small cell lung cancer patients.Scientific reports · 2025Article
- Targeting neutrophils for cancer therapy.Nature reviews. Drug discovery · 2025Review
- The safety and effectiveness of immune checkpoint blockade in lung cancer with COPD: a systematic review and meta-analysis.Journal of thoracic disease · 2025Article
- Machine learning assisted immune profiling of COPD identifies a unique emphysema subtype independent of GOLD stage.iScience · 2025Article
- Enhanced immunotherapy response in lung adenocarcinoma patients with COPD: insights into tumor cells and immune microenvironment characteristics.Cell communication and signaling : CCS · 2025Article
- Comorbidity of lung cancer and chronic obstructive pulmonary disease: correlation and optimization of treatment strategies.Translational lung cancer research · 2025Review
32 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
Abstract
rationaleChronic obstructive pulmonary disease (COPD) and non-small cell lung cancer (NSCLC) are interrelated diseases with substantial mortality, and the pathogenesis of both involves aberrant immune functioning.
objectivesTo profile immune cell composition and function in patients with NSCLC and describe the effects of COPD on lung and tumor microenvironments.
methodsWe profiled resected lung and tumor tissue using flow cytometry and T-cell receptor sequencing in patients with and without COPD from a prospective cohort of patients undergoing resection of NSCLC. A murine cigarette smoke exposure model was used to evaluate the effect on pulmonary immune populations. A separate retrospective cohort of patients who received immune checkpoint inhibitors (ICIs) was analyzed, and their survival was quantified. MEASUREMENTS AND MAIN
resultsWe observed an increased number of IFN-γ-producing CD8
conclusionsIn patients with COPD, Th1 cell populations were expanded in both lung and tumor microenvironments, and the presence of COPD was associated with longer progression-free intervals in patients treated with ICIs. This has implications for understanding the immune mediators of COPD and developing novel therapies for NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.